Important Information Regarding Vyzulta

Posted in Latest News on March 16, 2018.

During the March 9, 2018 Board of Optometry meeting, the board approved for addition to Rule 64B13-18.002 Formulary of Topical Ocular Pharmaceutical Agents, Vyzulta (latanoprostene bunod ophthalmic solution) 0.024%.

Important note, Vyzulta, at this time, cannot be prescribed by certified Optometrists in Florida until the rule has been approved. Once the rule has gone through the approval process, notice will be provided on this site, and at that time Vyzulta may be prescribed by certified optometrists.

 



More Latest News

System Maintenance Notice
July 14, 2020

Please be aware of system downtime for DOHMQA beginning Friday July 24th 6:30PM(EST) until Monday July 27th 6:00AM(EST). Click here for more information. Continue reading


Nonopioid Alternatives Pamphlet
July 1, 2020

2020 legislation amended the requirements for non-opioid alternatives. Click here to access the pamphlet for “Information on Nonopioid Alternatives for the Treatment of Pain” Continue reading